Pharmacist Information Hub

Checklist: Supplying S3 vapes

LIBER S3 Checklist

Checklist: Supplying S3 vapes

Step-by-step checklist to ensure compliance and clinical best practices when supplying S3 therapeutic vapes

Print / view online
Order now

Determine whether therapeutic vaping is appropriate for your patient

Vaping is appropriate for patients who:

  1. have failed to stop smoking using licensed pharmacotherapies; or
  2. are dependent on vaping products.

Assess the patient’s nicotine dependence

Patients may be considered to be lower dependence where:

  1. their time to first cigarette / vape after waking is more than 30 minutes; and
  2. they smoke fewer than 10 cigarettes per day.

For vaping, use (1.) only.

Determine which vape is appropriate for your patient

S3 vapes are appropriate as:

  1. the main therapeutic product for lower dependence patients; or
  2. as an interim measure for dependent patients until they can access S4 vapes.

Provide the patient with professional advice

Inform the patient

Ensure the patient understands that the vape you will dispense is not an ARTG listed or registered good.

Obtain and record the patient’s informed consent

Obtain the patient’s full name and date of birth

To faciliate the SAS-C notification lodgement to the TGA.

Supply S3 vapes

S3 may only be supplied for up to one month’s supply (i.e. 28 x Nicovape® Q20 cartridges).

IMPORTANT:

  1. Therapeutic vaping goods (both S3 and S4) must be supplied directly to the patient or their carer.
  2. Include the words ‘Do not swallow’ on the dispensing label of therapeutic vaping goods.
  3. Use Cautionary Advisory Label 21 (shown to the right) for all therapeutic vaping goods that contain nicotine to identify them as hazardous medicines.
Cautionary Advisory Label 21

Recommend follow-up

  1. For dependent patients, direct them to a specialist prescriber for ongoing care and appropriate therapeutic intervention.
  2. For less dependent patients, recommend smoking cessation support and in-pharmacy follow-up.

Complete SAS-C reporting within 28 days

Supplying and Dispensing Therapeutic Vapes

Request a pharmacy pack

Liber:Onboard

Onboard your pharmacy with Liber’s medical liaison team today

Liber:Activate

Establish your local GPs as activated authorised prescribers

Important links

Therapeutic Goods Administration

Pharmaceutical Society of Australia

References

  1. PSA Professional Practice Standard 1: https://www.psa.org.au/practice-support-industry/pps/
Nicovape Q products are TGA notified therapeutic vaping goods indicated for smoking cessation or the management of nicotine dependence. TGA Notification ID numbers: VG-2024-NTF-00234, VG-2024-NTF-00241, VG-2024-NTF-00240, VG-2024-NTF-00235, VG-2024-NTF-00242, VG-2024-NTF-00239, VG-2024-NTF-00237, VG-2024-NTF-00243, VG-2024-NTF-00238, VG-2024-NTF-00236.

© 2024 Liber Pharmaceuticals Ltd. All content

iNRT Healthcare is operated by Liber Pharmaceuticals for the purpose of furthering healthcare education regarding Nicotine Vaping Products (NVPs) within the Australian medical framework. Liber has no affiliation with the tobacco industry, their affiliates, or any organisations or individuals engaged in lobbying on their behalf.

This site is intended for use only by Australian-registered healthcare professionals with an interest in smoking cessation. It is not intended for use by consumers.